Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lilly to close Surrey neuroscience research site

by Lisa M. Jarvis
October 19, 2019 | A version of this story appeared in Volume 97, Issue 41

 

As part of a review of its R&D network, Eli Lilly and Company will close its neuroscience research center in Surrey, England, by the end of 2020. According to Lilly, consolidation over the years has left the site with fewer than 45 neuroscientists and 35 chemists. Remaining neuroscience activities will be shifted to the firm’s site in Cambridge, Massachusetts, while a small number of staffers will move to its Indianapolis research hub. The closure is expected to cost 80 of the 270 jobs in Surrey.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.